Drug Profile
Dapivirine - International Partnership for Microbicides
Alternative Names: AIDS-105293; Dapivirine - Janssen Sciences Ireland UC; Dapivirine ring 004; Dapivirine ring-008; Dapivirine vaginal ring; R-147681; TMC-120Latest Information Update: 10 Apr 2023
Price :
$50
*
At a glance
- Originator Tibotec BVBA
- Developer International Partnership for Microbicides; Janssen Sciences Ireland UC; National Institute of Allergy and Infectious Diseases
- Class Aniline compounds; Antivirals; Benzonitrile; Pyrimidines; Small molecules
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered HIV-1 infections
Most Recent Events
- 19 Feb 2023 Adverse events data from the phase III DELIVER trial in HIV-1 infections presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023 (CROI-2023)
- 19 Feb 2023 Initial pharmacokinetics and safety data from a phase IIIb trial in HIV infections presented at the 30th Conference on Retroviruses and Opportunistic Infections (CROI-2023)
- 16 Jun 2022 International Partnership for Microbicides plans a phase I bioavailability trial in HIV Infections (Prevention)(Vaginal, Ring), in June 2022 (NCT05416021)